US 10023654
Anti-PCSK9 antibodies
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 10023654 (Anti-PCSK9 antibodies) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K39/08, A61P